Takeda’s Livtencity approved in Japan for CMV

24 June 2024

The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Livtencity (maribavir) for post-transplant cytomegalovirus (CMV) infection/disease that is refractory to existing anti-CMV therapies, Japanese pharma major Takeda (TYO: 4502) announced today.

The company noted that Livtencity is the first and only post-transplant anti-CMV treatment approved in Japan that targets and inhibits pUL97 kinase and its natural substrates.

European Commission (EC) granted approval for the marketing authorization application for Livtencity in this indication in November 2022, and China’s National Medical Products Administration (NMPA) did likewise in December last year. The drug is also approved in the USA and Canada. Takeda has previously projected $700 million to $800 million in peak sales for Livtencity.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK